Sinusitis - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Sinusitis - Pipeline Review, H1 2016', provides an overview of the Sinusitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Sinusitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sinusitis and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Sinusitis - The report reviews pipeline therapeutics for Sinusitis by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Sinusitis therapeutics and enlists all their major and minor projects - The report assesses Sinusitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Sinusitis Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Sinusitis - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Sinusitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Sinusitis Overview 7 Therapeutics Development 8 Pipeline Products for Sinusitis - Overview 8 Sinusitis - Therapeutics under Development by Companies 9 Sinusitis - Pipeline Products Glance 10 Late Stage Products 10 Clinical Stage Products 11 Early Stage Products 12 Sinusitis - Products under Development by Companies 13 Sinusitis - Companies Involved in Therapeutics Development 14 Amgen Inc. 14 F. Hoffmann-La Roche Ltd. 15 Knopp Biosciences LLC 16 Merck & Co., Inc. 17 Oticpharma Ltd 18 Paratek Pharmaceuticals, Inc. 19 Regeneron Pharmaceuticals, Inc. 20 Therabron Therapeutics, Inc. 21 Sinusitis - Therapeutics Assessment 22 Assessment by Monotherapy Products 22 Assessment by Target 23 Assessment by Mechanism of Action 25 Assessment by Route of Administration 27 Assessment by Molecule Type 29 Drug Profiles 31 AMG-282 - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 CG-201 - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 dexpramipexole dihydrochloride - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 dupilumab - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 fluticasone propionate - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 omadacycline tosylate - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 omalizumab - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 P-008 - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 PCL-1404 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 Qi-117 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 Small Molecule for Sinusitis - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 Small Molecules for Chronic Rhinosinusitis - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 solithromycin - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 Sinusitis - Recent Pipeline Updates 54 Sinusitis - Dormant Projects 75 Sinusitis - Product Development Milestones 76 Featured News & Press Releases 76 Feb 03, 2016: Nasal polyps can be treated with medicine dupilumab 76 Feb 02, 2016: Sanofi and Regeneron Announce Publication of Positive Phase 2 Dupilumab Data in the Journal of the American Medical Association 76 Jun 23, 2015: Jubilant Life Sciences receives ANDA approval for Levofloxacin Tablets 77 Sep 30, 2014: Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 77 Appendix 79 Methodology 79 Coverage 79 Secondary Research 79 Primary Research 79 Expert Panel Validation 79 Contact Us 79 Disclaimer 80
List of Tables
Number of Products under Development for Sinusitis, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Comparative Analysis by Late Stage Development, H1 2016 10 Comparative Analysis by Clinical Stage Development, H1 2016 11 Comparative Analysis by Early Stage Development, H1 2016 12 Products under Development by Companies, H1 2016 13 Sinusitis - Pipeline by Amgen Inc., H1 2016 14 Sinusitis - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 15 Sinusitis - Pipeline by Knopp Biosciences LLC, H1 2016 16 Sinusitis - Pipeline by Merck & Co., Inc., H1 2016 17 Sinusitis - Pipeline by Oticpharma Ltd, H1 2016 18 Sinusitis - Pipeline by Paratek Pharmaceuticals, Inc., H1 2016 19 Sinusitis - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016 20 Sinusitis - Pipeline by Therabron Therapeutics, Inc., H1 2016 21 Assessment by Monotherapy Products, H1 2016 22 Number of Products by Stage and Target, H1 2016 24 Number of Products by Stage and Mechanism of Action, H1 2016 26 Number of Products by Stage and Route of Administration, H1 2016 28 Number of Products by Stage and Molecule Type, H1 2016 30 Sinusitis Therapeutics - Recent Pipeline Updates, H1 2016 54 Sinusitis - Dormant Projects, H1 2016 75
List of Figures
Number of Products under Development for Sinusitis, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Comparative Analysis by Clinical Stage Development, H1 2016 11 Comparative Analysis by Early Stage Products, H1 2016 12 Assessment by Monotherapy Products, H1 2016 22 Number of Products by Targets, H1 2016 23 Number of Products by Stage and Targets, H1 2016 23 Number of Products by Mechanism of Actions, H1 2016 25 Number of Products by Stage and Mechanism of Actions, H1 2016 25 Number of Products by Routes of Administration, H1 2016 27 Number of Products by Stage and Routes of Administration, H1 2016 27 Number of Products by Molecule Types, H1 2016 29 Number of Products by Stage and Molecule Types, H1 2016 29
Global activated carbon market size is likely to be valued at USD 5.3 billion by 2020; as per a new research report by Radiant Insights, Inc. Increase in commercial & residential waste water treatment demand owing to escalation in water prices is antRead More...
U.S hairbrush market is estimated to exceed USD 1.2 billion by 2022, as per a new research report by Radiant Insights, Inc. Rising population along with ascending disposable income is expected to drive industry demand. Significant rise in disposableRead More...
Global gold nanoparticles market size is expected to reach 4.99 billion by 2020, witnessing gains at a CAGR of 24.7%. Positive outlook towards the increasing applications of nanotechnology in medical and dentistry such as drug delivery systems, nanomRead More...
Global data center UPS market size is estimated to reach USD 5.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Declining tolerance levels pertaining to data loss along with amplifying acceptance of cloud computing is likelyRead More...
Global alpha olefins market size is likely to be valued at USD 10.7 billion by 2020; as per a new research report by Radiant Insights, Inc. Increasing polyethylene demand for use in plastic production is anticipated to drive market growth. Growing apRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.